Radical new approach to schizophrenia treatment begins trial

Exclusive: as evidence emerges that schizophrenia could be an immune system disease, two-year trial will use antibody drug currently used for MS

British scientists have begun testing a radically new approach to treating schizophrenia based on emerging evidence that it could be a disease of the immune system.

The first patient, a 33-year old man who developed schizophrenia after moving to London from Cameroon a decade ago, was treated at King's College Hospital in London on Thursday, marking the start of one of the most ambitious trials to date on the biology of the illness and how to treat it.